Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visx v. Nidek ITC LASIK Ruling May Open Door For Bausch & Lomb, Others

This article was originally published in The Gray Sheet

Executive Summary

A recent ruling by the International Trade Commission weakens, at least temporarily, the patent position of Visx and co-licensor Summit Technology in the rapidly growing laser-assisted in situ keratomileusis (LASIK) market, and creates an opening for a formidable competitor, Bausch & Lomb, whose Technolas LASIK device awaits FDA approval.

You may also be interested in...



Alcon's Summit Buy Highlights Increasing Consolidation In Ophthalmic Sector

Alcon Labs' recent decision to purchase Summit Autonomous signals a wider trend of consolidation in the ophthalmic device arena, a sector often dismissed by the investment community in recent years as lacking high-growth potential.

Alcon's Summit Buy Highlights Increasing Consolidation In Ophthalmic Sector

Alcon Labs' recent decision to purchase Summit Autonomous signals a wider trend of consolidation in the ophthalmic device arena, a sector often dismissed by the investment community in recent years as lacking high-growth potential.

LaserSight Views Pricing Options As Key To LaserScan Marketing Plan

LaserSight is highlighting its flexible payment and pricing scheme for its firm's LaserScan LSX ophthalmic excimer laser system as the firm gears up to compete with market leader Visx, with which it withdrew from patent licensing negotiations on Feb. 1.

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel